Mazdutide (IBI362)

Mazdutide earns a neutral score because the science is strong but the access and cardiac questions are not yet resolved. If your specific goal is liver fat, mazdutide posts the best published incretin numbers anywhere, roughly 72 to 80 percent reduction, per Ji 2025, and that is a real reason to watch this drug closely. For general weight loss, the honest call is that FDA-approved tirzepatide delivers comparable results with a prescription, pharmaceutical-grade quality, and cardiovascular outcomes data mazdutide does not have. The biggest cautions are the China-only approval, the grey-market reality in the West, and the glucagon-driven heart-rate signal that makes misdosing higher-stakes than with a pure GLP-1.

✅ Best for: People whose primary target is liver fat, where mazdutide's glucagon-driven hepatic effect is genuinely differentiated. Researchers and informed self-experimenters tracking the dual-agonist class who understand the data is Chinese-population-only. Anyone who can source verified pharmaceutical-grade material rather than untested powder, and who will monitor heart rate, glucose, and liver enzymes through dosing. People without cardiac risk factors, since the heart-rate effect matters most for those starting with a fast or borderline pulse.

❌ Avoid if: You have a personal or family history of medullary thyroid cancer, because of the class C-cell tumor warning. You have a history of pancreatitis, given the class pancreatitis signal. You have meaningful cardiovascular disease or arrhythmia, since the glucagon leg raises heart rate and no cardiovascular outcomes trial has cleared it. You want a legal, prescribable option with quality control, in which case approved alternatives fit better. You cannot verify source quality, because grey-market contamination risk compounds the drug's own glucagon-driven dangers.